ANO9: A Potential Drug Target and Biomarker (G338440)

Target Name: ANO9

NCBI ID: G338440

ANO9

ANO9: A Potential Drug Target and Biomarker

Anno9 is a small non-coding RNA molecule that has been identified as a potential drug target and biomarker for several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique structure and biology have made it an attractive target for researchers to study, and recent studies have suggested that ANO9 may have a significant impact on disease progression.

ANO9 is a non-coding RNA molecule that consists of 92 amino acid residues. It is expressed in a variety of tissues and cells, including the brain, heart, liver, and pancreas, and has been shown to play a role in several biological processes. One of the most significant functions of ANO9 is its role in the regulation of gene expression. ANO9 has been shown to interact with various transcription factors and regulates the expression of genes involved in cell growth, differentiation, and survival.

One of the most promising aspects of ANO9 is its potential as a drug target. Its unique structure and biology have made it an attractive target for researchers to study, and recent studies have suggested that ANO9 may have a significant impact on disease progression.

ANO9 has been shown to play a role in the regulation of cell cycle progression. It has been shown to interact with the protein kinase B-complex, which is involved in cell cycle regulation. Studies have shown that ANO9 can inhibit the activity of the protein kinase B-complex, which may have implications for the regulation of cell cycle progression and the development of cancer.

ANO9 has also been shown to play a role in the regulation of cell survival. It has been shown to interact with the protein p53, which is involved in the regulation of DNA damage repair. Studies have shown that ANO9 can inhibit the activity of the protein p53, which may have implications for the regulation of cell survival and the development of neurodegenerative diseases.

ANO9 has also been shown to play a role in the regulation of inflammation. It has been shown to interact with the protein NF-kappa-B, which is involved in inflammation regulation. Studies have shown that ANO9 can inhibit the activity of the protein NF-kappa-B, which may have implications for the regulation of inflammation and the development of autoimmune disorders.

In addition to its potential as a drug target, ANO9 has also been shown to be a potential biomarker for several diseases. Its unique structure and biology have made it an attractive target for researchers to study, and recent studies have suggested that ANO9 may have a significant impact on disease progression.

ANO9 has been shown to play a role in the regulation of stem cell proliferation. It has been shown to interact with the protein Oct-4, which is involved in the regulation of stem cell proliferation. Studies have shown that ANO9 can inhibit the activity of the protein Oct-4, which may have implications for the regulation of stem cell proliferation and the development of cancer.

ANO9 has also been shown to play a role in the regulation of tissue repair. It has been shown to interact with the protein Tissue Adaptation factor-1, which is involved in tissue repair. Studies have shown that ANO9 can inhibit the activity of the protein Tissue Adaptation factor-1, which may have implications for the regulation of tissue repair and the development of neurodegenerative diseases.

In conclusion, ANO9 is a small non-coding RNA molecule that has been identified as a potential drug target and biomarker for several diseases. Its unique structure and biology have made it an attractive target for researchers to study, and recent studies have suggested that ANO9 may have a significant impact on disease progression. Further research is needed to fully understand the role of ANO9 in biology and its potential as a drug target.

Protein Name: Anoctamin 9

Functions: Has calcium-dependent phospholipid scramblase activity; scrambles phosphatidylserine, phosphatidylcholine and galactosylceramide (By similarity). Does not exhibit calcium-activated chloride channel (CaCC) activity (PubMed:22178883). Can inhibit the activity of ANO1 (PubMed:20056604, PubMed:22946059)

The "ANO9 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ANO9 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets